INR 5,375
bility CLICK TO EDIT MASTER TITLE STYLE KEY HIGHLIGHTS Overall Revenue EBITDA R&D Investment1 INR 5,375 Cr INR 1,143 Cr 2% overall YoY growth 6% Ex-covid YoY growth 21.3% Margin Core margin tra
INR 1,143
TO EDIT MASTER TITLE STYLE KEY HIGHLIGHTS Overall Revenue EBITDA R&D Investment1 INR 5,375 Cr INR 1,143 Cr 2% overall YoY growth 6% Ex-covid YoY growth 21.3% Margin Core margin trajectory intact
2%
TITLE STYLE KEY HIGHLIGHTS Overall Revenue EBITDA R&D Investment1 INR 5,375 Cr INR 1,143 Cr 2% overall YoY growth 6% Ex-covid YoY growth 21.3% Margin Core margin trajectory intact; des
6%
HTS Overall Revenue EBITDA R&D Investment1 INR 5,375 Cr INR 1,143 Cr 2% overall YoY growth 6% Ex-covid YoY growth 21.3% Margin Core margin trajectory intact; despite sharp normalisation
21.3%
DA R&D Investment1 INR 5,375 Cr INR 1,143 Cr 2% overall YoY growth 6% Ex-covid YoY growth 21.3% Margin Core margin trajectory intact; despite sharp normalisation in covid portfolio contribu
INR 274
ectory intact; despite sharp normalisation in covid portfolio contribution compared to Q1FY22 INR 274 Cr 4% YoY growth 5.1% of overall revenue BUSINESS UNIT-WISE REVENUE & YOY GROWTH One-India No
4%
t; despite sharp normalisation in covid portfolio contribution compared to Q1FY22 INR 274 Cr 4% YoY growth 5.1% of overall revenue BUSINESS UNIT-WISE REVENUE & YOY GROWTH One-India North Am
5.1%
p normalisation in covid portfolio contribution compared to Q1FY22 INR 274 Cr 4% YoY growth 5.1% of overall revenue BUSINESS UNIT-WISE REVENUE & YOY GROWTH One-India North America SA Private
9%
SINESS UNIT-WISE REVENUE & YOY GROWTH One-India North America SA Private International Markets 9% (ex-covid) YoY growth in INR terms 10% YoY growth in $ terms 8% YoY growth in ZAR terms 18
10%
e-India North America SA Private International Markets 9% (ex-covid) YoY growth in INR terms 10% YoY growth in $ terms 8% YoY growth in ZAR terms 18% YoY growth in $ terms Continued core
8%
ivate International Markets 9% (ex-covid) YoY growth in INR terms 10% YoY growth in $ terms 8% YoY growth in ZAR terms 18% YoY growth in $ terms Continued core portfolio momentum across t
18%
9% (ex-covid) YoY growth in INR terms 10% YoY growth in $ terms 8% YoY growth in ZAR terms 18% YoY growth in $ terms Continued core portfolio momentum across therapies and business segments